Severe cases of COVID-19 are characterized by hyperinflammation induced by cytokine
storm, ARDS leading to multiorgan failure and death. JAK-STAT signaling has been …

Objectives This systematic review and meta-analysis of randomized controlled trials (RCTs)
aimed to investigate the clinical efficacy and safety of Janus kinase (JAK) inhibitors for …

The interferon pathway, a key antiviral defense mechanism, is being considered as a
therapeutic target in COVID‐19. Both, substitution of interferon and JAK/STAT inhibition to …

Dexamethasone (Dex) is used in drug regimen for treatment of Coronavirus disease (COVID-
19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) fusion and entry into …

The highly pathogenic, novel coronavirus disease (COVID-19) outbreak has emerged as a
once-in-a-century pandemic with poor consequences, urgently calling for new therapeutics …

Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in
patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18 …

The COVID-19 pandemic has inflicted millions of deaths worldwide. Despite the availability
of several vaccines and some special drugs approved for emergency use to prevent or treat …

JAK inhibitors are novel treatment agents in the field of infectious diseases. One JAK
inhibitor, baricitinib has demonstrated significant clinical and survival benefits in hospitalized …

During the current pandemic, the vast majority of COVID-19 patients experienced mild
symptoms, but some had a potentially fatal aberrant hyperinflammatory immune reaction …

Objectives Prone positioning is widely used in mechanically ventilated patients with COVID-
19; however, the specific clinical scenario in which the individual is most poised to benefit is …